Browsing by Author "Boz, Cavit"
Now showing items 1-4 of 4
-
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
Boz, Cavit; Terzi, Murat; Ozer, Bilge; Turkoglu, Recai; Karabudak, Rana; Efendi, Husnu; Ozakbas, Serkan (Elsevier Sci Ltd, 2019)Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with ... -
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
Fragoso, Yara Dadalti; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Vucic, Steve; Haartsen, Jodi (Elsevier Sci Ltd, 2018)Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed ... -
Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]
Fragoso, Yara Dadalti; Brooks, Joseph Bruno B.; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Haartsen, Jodi (Elsevier Sci Ltd, 2018)… -
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis
Boz, Cavit; Terzi, Murat; Karahan, Serap Zengin; Sen, Sedat; Sarac, Yasemin; Mavis, Murat Emrah (Sage Publications Ltd, 2018)Background: Women with multiple sclerosis (MS) experience an increased risk of relapse in the postpartum period. High-dose methylprednisolone is the first-line treatment for acute relapses. Objectives: To determine the ...
